Log in to save to my catalogue

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderli...

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderli...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_86604cdf338e458589ae44c27f7b2e8a

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)

About this item

Full title

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)

Publisher

Japan: John Wiley & Sons, Inc

Journal title

Annals of Gastroenterological Surgery, 2023-11, Vol.7 (6), p.997-1008

Language

English

Formats

Publication information

Publisher

Japan: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
Nab‐paclitaxel plus gemcitabine is a standard treatment for metastatic/locally advanced pancreatic cancer. The effectiveness of neoadjuvant therapy with nab‐paclitaxel plus gemcitabine (GnP‐NAT) in patients with borderline resectable pancreatic cancer (BRPC) remains unclear.
Patients and Methods
This single‐arm phase II trial in...

Alternative Titles

Full title

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_86604cdf338e458589ae44c27f7b2e8a

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_86604cdf338e458589ae44c27f7b2e8a

Other Identifiers

ISSN

2475-0328

E-ISSN

2475-0328

DOI

10.1002/ags3.12712

How to access this item